Business News


Stocks Roars Again- Baxter International Inc. (NYSE:BAX), Chicago Bridge & Iron Company N.V. (NYSE:CBI), Monsanto Company (NYSE:MON)

Baxter International Inc. (NYSE:BAX) released that completion of CE marking (market approval) in Europe for HOMECHOICE CLARIA, an automated

Tech News


Unexpected Moves in Focus: FirstEnergy Corp. (NYSE:FE), Bellatrix Exploration Ltd. (NYSE:BXE), BankUnited, Inc. (NYSE:BKU)

A subsidiary of FirstEnergy Corp. (NYSE:FE) [Trend Analysis] announced its Perry Nuclear Power Plant in Perry, Ohio, FirstEnergy Nuclear

General News

stock news

FuelCell Energy (NASDAQ:FCEL) Swings on Major Declaration- Golar LNG (NASDAQ:GLNG), FedEx (NYSE:FDX), Archer-Daniels-Midland (NYSE:ADM)

FuelCell Energy Inc (NASDAQ:FCEL) (Full FREE Analysis of FCEL And Be Sure To Notice The Intermediate Period) released its fourth quarter



Dominion Resources (NYSE:D) Swings on Declaration- Cablevision Systems (NYSE:CVC), GlaxoSmithKline (NYSE:GSK), Harris (NYSE:HRS)

Dominion Resources, Inc. (NYSE:D) released that its fourth quarter earnings of $0.84 a share, excluding non-recurring items. The firm



Stocks in News: Gevo, Inc. (NASDAQ:GEVO), Ericsson (NASDAQ:ERIC), Boston Scientific Corporation (NYSE:BSX)

Gevo, Inc. (NASDAQ:GEVO) reported that 1-for-15 Reverse Stock Split. The 1-for-15 reverse stock split will be effective as of the close



Johnson & Johnson (NYSE:JNJ) Under Pressure on New Entrance- Silvercorp Metals (NYSE:SVM), Medtronic (NYSE:MDT), The Charles Schwab (NYSE:SCHW)

Johnson & Johnson (NYSE:JNJ) dropped around 2% in last session as Janssen Pharma declared that it will invest in a novel scientific approach, called disease interception, to find ways to intercept type 1 diabetes using new diagnostic and pre-disease intervention strategies. This new approach to T1D is the initial in a series of disease areas to be tackled as part of Janssen's newly announced Disease Interception Accelerator, an autonomous incubator-like group that seeks to identify the root causes of disease and enable the development of interventions that stop the progression to disease. Whereas, shares of Johnson & Johnson (NYSE:JNJ) traded down of -1.93% to finished at USD98.44 with market capitalization